Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 6, 2016
Primary Health Properties appoint new Directors
Primary Health Properties PLC, a UK-based investor in modern primary healthcare facilities, has appointed Geraldine Kennell and Nick Wiles to the Board as independent non-executive Directors.
April 5, 2016
Diplomat’s Taltz approved for treatment of plaque psoriasis
TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.
April 5, 2016
New U.S. inversion rules threaten Pfizer-Allergan deal
The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
March 29, 2016
Sanofi poaches AstraZeneca scientist as new research head
drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.
March 23, 2016
AstraZeneca’s Brilianta tablets efficient in prevention of major vascular events
AstraZeneca on Wednesday announced the results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90 mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA)
March 22, 2016
Drugmaker Valeant CEO leaving as investor Ackman joins the board
Drugmaker Valeant Pharmaceuticals International Inc said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business.
March 22, 2016
Verona Pharma: “A successful year with significant progress”
Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, has provided a summary review of its 2015 performance.
March 22, 2016
Skypharma apply for listing 1,1M £1.00 ordinary shares of to trade on LSE
Skyepharma has made an application to the UK Listing Authority (UKLA) and the London Stock Exchange for the listing of 1,100,000…
March 17, 2016
Allergan: FDA approves Vraylartm
Allergan’s Vraylartm (cariprazine), a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the U.S. As Allergan…